IperionX: Camden Acquisition and Pentagon Dollars Can't Halt the Selloff

Shares fall on cash burn and dilution fears, overshadowing $6.6M DoD funding and Camden acquisition that expands titanium footprint.

A flurry of operational milestones failed to lift IperionX's shares on Thursday, as investors zeroed in on the company's cash burn and dilution risk. The stock tumbled 6.49% to €2.52, erasing any goodwill from a fresh Pentagon grant and a completed land deal in Tennessee—a sign that the market remains deeply skeptical about the timeline to revenue.

The Camden project in Tennessee, now fully acquired for roughly $3 million, sits adjacent to IperionX's existing titanium site in the Big Sandy critical minerals region. The company highlighted four value drivers from the transaction: a sharp expansion of the combined Camden-titanium footprint, about 70 hectares of ultra-high-grade surface deposits, some 180 hectares of pre-stripped mineral occurrences with virtually no overburden, and existing infrastructure including a rail spur. Decades of high-purity silica sand mining have effectively pre-processed the heavy mineral fractions, yielding surface-near deposits rich in titanium, zircon and rare earths. Company sampling returned total heavy mineral grades of up to 21.5%.

That deal landed just a day after IperionX secured as much as $6.6 million from the U.S. Department of Defense for domestic production of high-performance titanium alloys, including ballistic plates for military vehicles. The funding arrives in two tranches: $200,000 for initial project planning and testing, followed by $6.4 million for equipment purchases and capacity expansion. Separately, the U.S. Army placed an order for titanium fasteners for the Joint Light Tactical Vehicle, using IperionX's HAMR process that produces low-cost titanium powder from recycled scrap.

Despite the positive news flow, the stock remains deep in the red. It now sits 50.47% below its 52-week high of €5.09, reached on January 26, and about 39% above its low of €1.82 from March 23. The 50-day moving average of €2.99 and the 200-day moving average of €3.43 both stand well above the current price, underscoring the bearish momentum. Monthly losses amount to 33.08%, while the year-to-date decline is 23.61%. The stock's 30-day annualized volatility runs at nearly 84%, reflecting persistent nervousness in the name.

A big part of the market's concern stems from the company's financial profile. IperionX has yet to generate revenue and is burning over $30 million in losses, funding itself repeatedly through capital raises. That dilution overhang likely weighed on the stock even as the operational headlines turned positive. One analyst described the Camden deal as a strategic fit—securing domestic raw materials, a powder plant, a press and validated components—but cautioned that converting rock samples into a bankable mineral resource still requires drilling, metallurgical testing and customer qualification.

Management is now racing to turn the acquisition into a credible resource. A sonic drilling program is underway, alongside metallurgical tests and infrastructure optimization. The company targets a formal resource classification under JORC and S-K 1300 standards this year, with an integrated Camden-titanium feasibility study due by the end of 2026. In the shorter term, IperionX must complete the first project phase for the Pentagon without a hitch to restore investor confidence. Until the feasibility study lands, the tug-of-war between a promising long-term raw materials story and near-term capital needs will keep the stock on a tight leash.